Product Description
Means of evaluating Injury of Cervical Spine and Cervical Spine Fractures (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01278511)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: KU LEUVEN
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Fracture Dislocation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IPSTRAUC | N/A |
Not yet recruiting |
Injuries/wounds Unspecified |
2029-01-01 |
2025-05-22 |
Primary Endpoints|Treatments |
|
| CTO 0769 | N/A |
Completed |
Neck Pain|Spinal Cord Injuries|Low Back Pain |
2018-04-30 |
2019-03-20 |
Treatments |
|
| 2009142-01H | N/A |
Completed |
Spinal Cord Injuries|Spinal Fractures |
2015-08-01 |
2019-03-19 |
||
| ACTRN12616001098426 | N/A |
Completed |
Other |
2015-04-16 |
2024-08-29 |
Treatments |
|
| S52940 | N/A |
Withdrawn |
Spinal Fractures|Spinal Injuries |
None |
2019-03-19 |
Treatments |
|
| MOP-86709 | P4 |
Completed |
Fracture Dislocation |
2010-07-01 |
2019-03-19 |
Treatments |